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Tuberculosis (TB) is an important global public health problem. Although 
increasing, the prevalence of TB in Norway is low, however the situation 
changes completely crossing the border to our neighbor country Russia. We 
wanted to learn more about management of TB, the global TB situation and 
the situation in Russia. 
 
Materials and methods 
We made a study tour to Arkhangelsk and visited the Arkhangelsk 
Antituberculosis Dispensary to learn some of the basics about TB care in 
high prevalence settings. Back in Norway we used WHO reports, searched 
in the PubMed database and other written sources to gather the appropriate 
information. 
 
Results and interpretations 
According to the WHO, TB caused 1,7 million deaths in 2009. For the last 
decades considerable resources have been mobilized in the fight against TB. 
The WHO indicators tell that the situation is improving at a global level, but 
there are still challenges to overcome. One of them is the high incidence of 
multi-drug resistant TB, as in Arkhangelsk Oblast in the Russian Federation. 
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Although Norway is a country with low prevalence of tuberculosis, the 
disease is a threat to global health. Considering as well, the high prevalence 
in the northwestern parts of Russia, we thought it could be useful to learn 
more about TB management in general and to give an overview of the 
current TB situation, both globally and in Russia. Spending time at the 
Antituberculosis Dispensary in Arkhangelsk in November 2009, provided 
us an inside view on the actual situation, and encouraged us to further 
investigate this health topic.  
 
We have tried to give an overview of the TB situation today, and want to 
include an understanding of why resistance has become such a considerable 
problem. 
 
We think that understanding the basic clinical aspects regarding TB is 
important for the overall understanding of the changes in the situation both 
in a global and local perspective. An overview of different clinical aspects 
therefore constitutes a considerable part of our paper. There are important 
topics regarding TB only mentioned briefly in this text. We chose to focus 
more on multi-drug resistant tuberculosis than comorbidity with HIV and 
TB, although the latter is a huge challenge globally. The reason for this was 
that multi-drug resistance is a problem in Arkhangelsk oblast and other 
regions in the northwestern part of Russia, whereas HIV/TB comorbidity is 
not, or at least to a much lesser extent than in a global perspective. We have 
also not chosen to focus on the controversy of BCG vaccine, or the 
difficulties of introducing new drug in treatment of TB, although both are 
highly interesting subject at the present. Also we have concentrated mainly 
on TB in adults, it must be mentioned that the disease presents differently in 
children. 
 
During the work on the thesis it has been necessary to make some changes 
from the original plan for the project. This plan included collecting statistics 
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from the Arkhangelsk region during our stay at the Antituberculosis 
Dispensary in Arkhangelsk city. Because of linguistic difficulties among 
other reasons, we had to change our plans in regard to this. Anyhow our stay 
in Arkhangelsk was most valuable to us, considering the opportunity we had 
to experience the different apartments of the dispensary, like the laboratory 
department, the different inn-patients departments, epidemiology 
department and so on. All this was only possible by the welcoming and 
helpful staff at the dispensary. 
 
3 Materials and methods  
 
The basis for our thesis is a literature study. When finding information, facts 
from the World Health Organization are essential. We have used WHO 
publications and guidelines in our work. We have also searched the PubMed 
database for articles related to TB, information available from web sites of 
organizations working in the TB field, and textbooks. In addition, we did a 
study tour to Arkhangelsk and spent time at the Antituberculosis 
Dispensary. 
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4 Basic science of tuberculosis 
4.1 Characteristics of Mycobacterium tuberculosis 
 
M. tuberculosis is a fairly large non-motile aerobic bacterium. It is obligate 
aerobic, thus it can only survive in an oxygen-containing environment. The 
rods are 2-4 micrometers in length and 0.2-0.5 um in width. [1] The cell 
envelope is composed by a core of three macromolecules covalently linked 
to each other (peptidoglycan, arabinogalactan and mycolic acids), and a 
lipopolysaccharide (lipoarabinomannan), which is thought to be anchored to 
the plasma membrane. [2] 
 
The bacterium divides slowly, with 16-20 hours between each cell division. 
Other bacteria usually divide in less than an hour, and the fastest-growing 
strain of E. coli divide roughly every 20 minutes. [3] 
 
4.1.1 Exposure and primary infection 
Practically, the only reservoir of M. tuberculosis that contributes to 
spreading TB-infection is the patient with pulmonary TB, with their chronic 
respiratory symptoms such as cough and sputum production. When they 
cough, speak or sneeze they produce aerosol droplets from the bronchi. [4] 
Aerosols are solid or liquid particles in a gas, with a size from 0.001 to over 
100 µm. A single sneeze can release 40 000 droplets, and a cough about 
3000 droplet nuclei, the same number as talking for 5 minutes. [5] When 
they come in contact with air they dry rapidly and become very light 
particles that still contain live bacilli, and remain suspended for a long time. 
[4] 
 
When the bacteria penetrate the pulmonary alveoli of a healthy person, they 
are phagocytized by macrophages, in which they multiply. This creates a 
response where other macrophages and monocytes are attracted and 
participate in defense against the infection. This creates a primary focus; an 
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infectious focus made up of inflammatory cells. [4] This is also called the 
Ghon focus. [5] 
  
The bacteria and its antigens are drained by the macrophages to the nearest 
lymph node through the lymphatic system. Inside the lymph node, the 
antigens are recognized by T-lymphocytes, leading to transformation into 
specific CD4 and CD8 lymphocytes and liberation of lymphokines such as 
interferon-γ. This activates macrophages to kill intracellular mycobacteria 
and/or inhibit the growth of the phagocytized bacilli.  
The specific lymphocytes are central to TB immunity. Their fundamental 
role is demonstrated in studies of HIV-infected individuals. These have a 
reduced number of specific circulating lymphocytes, in particular CD4 
lymphocytes, which diminish as their disease develops. This is why they are 
more likely to develop TB following infection. [4, 6]  
 
In the primary focus, inflammatory tissue is formed and later replaced by 
scar tissue in which the immune cells containing M. tuberculosis are 
isolated and die. This is basis for the site of TB-specific necrosis. It contains 
1000- 10 000 bacteria which gradually multiply more slowly. Some become 
latent bacilli that can survive for years. The same event occurs in the lymph 
node, and caseating lymph nodes are formed. These resolve toward fibrosis 
followed by calcification, in the majority of cases. [4] 
 
Some infected individuals never develop active disease, but the reason is not 
fully understood. In 1926 newborn infants from Lübeck in Germany 
received live M. tuberculosis instead of the vaccine BCG. Some were 
unaffected, while others became gravely ill. This indicates that at least some 
individuals produce an effective immune response; in addition this episode 
in infants known to have immature adaptive immunity suggests that the 
innate host defense is an important anti-mycobacterial host defense. [6] 
 
Immunity due to the formation of circulating antibodies plays a marginal 
role in TB, as the mycobacteria are resistant to the direct effect of antibodies 
and their products. [4] 
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4.1.2 Development of secondary foci 
Bacteria from the primary infectious focus or nearest lymph node are 
transported throughout the body by the lymph system and bloodstream, 
constituting secondary foci of infection. These are in particularly in the 
liver, bones, kidneys and meninges. Due to immune response most of these 
foci resolve, but many bacteria may remain latent for months or even years. 
[4] 
 
4.2 Pulmonary and Extrapulmonary Tuberculosis 
 
Approximately 85% of reported TB cases were limited to the lungs, before 
the beginning of the HIV epidemic. The remaining 15% involved only non-
pulmonary or both pulmonary and non-pulmonary sites. This has changed 
with the involvement of HIV, and although the distribution amongst the 
HIV positive population has not been described in any national data, studies 
describe a percentage of approximately 33% in each category (pulmonary, 
non-pulmonary, both). [7] A person with active but untreated TB can infect 
10–15 other people per year. [8] 
 
4.2.1 Pulmonary TB 
Pulmonary TB occurs in a previously infected individual when there are 
major amounts of bacteria, and/or in the presence of immune deficiency, but 
seldom due to progression during primary infection. It is more commonly 
seen by endogenous reactivation of bacteria that have remained latent after 
primary infection, or as a new infection in a previously infected individual 
(exogenous re-infection). In absence of treatment and immune deficiency, 
the risk of endogenous reactivation is estimated at 10% in 10 years 
following infection, and later 5%. 
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Untreated, 30% of patients will achieve cure by the body’s defense 
mechanisms, 50% die within 5 years, and 20% continue to remain sources 
of infection by continuing to excrete bacteria. [4] 
 
Symptoms usually develop over several weeks. Chest symptoms can mimic 
virtually any respiratory condition. Cough is almost always present, as 
inflammation and tissue necrosis ensue sputum is produced. Possibly the 
patient will experience chest pain and/or dyspnea as accompanying 
symptoms, usually due to spontaneous pneumothorax. Hemoptysis may 
occur, but does not necessarily indicate active TB; it may result from post-
TB bronchiectasis, rupture of dilated blood vessels in the wall of old 
cavities or bacterial/fungal infection, etc. [4, 7]  
 
Systemic symptoms (night sweat, fever in the evening, loss of appetite, 
fatigue) are nonspecific. [4] 
 
Physical findings are generally not helpful in defining the disease. Rales 
may be heard over the area of involvement and amphoric breath sounds may 
indicate cavities. [7] 
 
4.2.2 Extrapulmonary TB 
Extrapulmonary TB is defined as TB that affects any organ outside 
pulmonary parenchyma. It presents more of a diagnostic and therapeutic 
challenge than pulmonary TB. This relates to it being more uncommon, also 
it involves relatively inaccessible sites. [4, 7]  
 
Certain forms of TB occurring in sites that are fully or partially within the 
chest are also considered extrapulmonary:  
• Pleural TB and TB of the hilar or mediastinal lymph nodes are 
classified as extrapulmonary. 
• Disseminated TB is a form of the disease that affects many sites in 
the body simultaneously and is not limited to the lungs. [4] 
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Disseminated (miliary) TB and tuberculous meningitis are acute forms of 
TB infection caused by the haematogenous spread of the bacteria, often 
occurring soon after primary infection. They occur most often in children 
and young adults, with a peak incidence of meningitis in children > 4 years 
of age. These acute forms are highly fatal. [4, 7] 
 
The diagnosis of disseminated TB is based on clinical signs (general 
deterioration, high fever and dyspnea). Signs of involvement of other organs 
include: pleural effusion, digestive problems, hepato-splenomegaly and 
some times meningeal symptoms. It results in a characteristic chest 
radiography: a ”miliary” pattern may be seen; extensive, tiny (1-2 mm) 
nodules resembling millet seeds, all the same size and spread symmetrically 
over both lungs. [4] 
 
Meningitis is the most frequent form of CNS TB. The process takes place 
primarily at the base of the brain; hence symptoms include affection of 
cranial nerves (such as paralysis of the oculomotor nerve, leading to 
strabismus and/or ptosis and sometimes convulsions) in addition to 
headache, stiff neck and loss of consciousness. The diagnosis of 
tuberculosis meningitis is based on clinical signs, and cerebrospinal fluid 
obtained by lumbar puncture should be examined even if there are no clear 
meningeal signs. [4, 7]  
 
The other forms of extrapulmonary TB are not as life threatening as 
disseminated TB. They can however lead to complications and severe 
sequela: deficit of a vital function (respiratory, cardiac, hepatic or renal), 
important neurological deficits (due to compression of the spinal chord) or 
sterility (genital tuberculosis). [4] 
 
 
4.3 Diagnostics of Active Tuberculosis Infection 
According to the WHO standards for diagnosis, all persons with a 
productive cough lasting for two-three weeks or more, without any other 
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explanation should be evaluated for TB. After taking a medical history and 
a clinical examination, sputum specimens and chest-X-ray should be 
performed. If the patient is suspected of having extrapulmonary TB, the 
specimens should be taken from the site of infection. [9] Microscopy of the 
specimen, either sputum or from the site of involvement in extrapulmonary 
TB is done. When the appropriate equipment and resources are available, 
culture should be performed and in the case of extrapulmonary TB 
histopathological examination should be done as well. [9] 
 
According to the guidelines from the Norwegian Institute of Public Health, 
all patients in Norway in whom pulmonary TB is suspected will be 
examined with a chest-X-ray. If this is without findings, normally no more 
examinations are done. With findings, three sputum specimens for culture, 
microscopy and PCR are obtained. Treatment is started if the PCR or 
microscopy is positive for M. tuberculosis or if TB is still strongly 
suspected because of clinical findings. [10] 
 
4.3.1 Chest X-ray 
An adult patient with TB can have a chest X-ray showing infiltrates or 
consolidations and cavities. These are most commonly found in the 
posterior apical parts of the upper lobes, the apical segment of the lower 
lobes and then anterior segments of the upper lobes. It is not possible to 
distinguish TB from an ordinary pneumonia on a chest X-ray. In 
immunosuppressed patients the lesions seen on the x-ray can be more 
diffuse, or there are no findings at all. [10] 
 
4.3.2 Bacterial examination 
Bacterial examination in the patient with lung TB relies highly on sputum 
samples. The sample should be made from sputum from the lower 
respiratory tract, most often obtained by asking the patient to take a few 
deep breaths and then to cough. If possible, the specimen should be obtained 
early in the morning before the patient has had his first meal. At least three 
samples containing 5-10 ml each should be collected. [10] Extrapulmonal 
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TB is diagnosed according to localization; for meningitis they use 
cerebrospinal fluid, aspiration of lymph nodes, samples from the pleural 
cavity, etc. In a child who has difficulties expectorating on effort, gastric 
aspiration is used to diagnose pulmonary TB. [4] 
 
4.3.3 Direct microscopy on sputum samples 
Direct microscopy is important because it reveals if the patient is 
contagious, and the result can be obtained quickly, as soon as 1 hour after 
receipt of the specimen in the laboratory. [11] The method in use is the 
Ziehl-Neelsen staining. Due to the waxy cell walls of the mycobacteria, 
Gram staining cannot be used to diagnose TB. In the Ziehl-Neelsen 
procedure, heat is used to drive fuchsine stain into the mycobacteria. 
Decolorizing agents such as acid and alcohol will not remove the staining, 
hence the term acid-fast bacillus. [12] Other staining techniques are also 
available, the fluorescent dye auramine being one of them.  
 
The sensitivity of examining sputum with the Ziehl-Neelsen method is low. 
It requires 5 000-10 000 bacteria per ml sputum to see mycobacteria in 
direct microscopy. In this examination it is not possible to recognize M. 
tuberculosis from other mycobacteria. [10] With the Ziehl-Neelsen staining, 
acid-fast bacilli will appear as red rods against a blue background in the 
microscope. [13] This method is still the most used to diagnose TB in many 
countries, [14] although it has a low sensitivity (40-60%) and even lower 
when there is HIV/TB comorbidity (20%). The reason for this is the limited 
resources in many developing countries, where there is a large number of 
TB cases. [15] 
 
4.3.4 Culture  
When culture is to be performed, the specimen is first treated with certain 
bactericidal chemicals to avoid contamination by other bacteria. [16] 
Growth of M. tuberculosis in culture can take up to 8 weeks. [10] Both solid 
media and liquid media are used. Lövenstein-Jensen medium is the most 
common solid medium in use. It is an egg-based media made of mineral salt 
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solution, malachite green dye and homogenized eggs. Agar-based media are 
also in use. Some are selective agars containing antibiotics, in that way 
inhibiting contamination by non-mycobacterial agents that survived the 
initial decontamination procedure.  
 
Liquid media, like the BACTEC-method described later, give a much more 
rapid result. Within 2-3 weeks the growth of M. tuberculosis can be 
detected. Antimicrobial agents are added to the media to avoid 
contamination. [16] 
 
4.3.5 Differentiating Mycobacterium Tuberculosis 
There are several methods to differentiate M. tuberculosis from non-
tuberculous mycobacteria after culture. One method is high-pressure liquid 
chromatography (HPLC), which analyses the cell-wall lipids of the bacteria, 
comparing them to known patterns of mycobacterial species. Nucleic acid 
probes, and DNA sequencing are also in use. Among the conventional 
methods in use are the niacin test, nitrate reduction test, pyrazinamidase test 
and thiophene-2-carboxylic-acid hydrazide (TCH) susceptibility. These tests 
identify M. tuberculosis and differentiate it from M. bovis.  
M. tuberculosis will give niacin production and reduction of nitrate because 
of production of nitrate reductase. Many M. tuberculosis strains are 
susceptible to pyrazinamide whereas M. bovis are resistant because of 
pyrazinamidase production. M. bovis is the only mycobacteria susceptible 
to TCH, and will not grow when TCH is added to the medium. [16] 
 
4.3.6 Susceptibility Testing 
The high rates of resistance among M. tuberculosis-strains makes 
susceptibility testing important to avoid further development of resistance 
among the M. tuberculosis-strains. In the last years new methods of 
susceptibility testing are developed. In general these methods are faster than 
the conventional methods but at the same time more expensive, making 
them less available for countries with low income, and lack of adequate 
human resources and equipment. [17] 
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The conventional methods are still the most common in many countries. 
Among them are the absolute concentration method, the resistance-ratio 
method and the proportion method. The low costs comparing to other newer 
methods, and the fact that they are highly standardized for testing 
susceptibility on many drugs make them preferable in many countries. Their 
disadvantages are, as stated above, the prolonged time before the results are 
available. In addition to the 8 weeks it can take before pulmonary TB is 
confirmed, another six weeks are required for the drug susceptibility test 
results.  [13] 
 
The proportion method is preferred among the three methods, and will 
therefore be described shortly. This method gives information on the 
proportion of resistant bacteria among the total number of bacteria in the 
strain. Two dilutions made from the standard suspension of tubercle bacilli 
from the primary culture and distilled water are inoculated on to sets of 
tubes with the Löwenstein-Jensen media, one containing the drug and 
another without drug. [18] After 28 days the number of colonies in the tubes 
containing drug and the number of colonies in the tube not containing drug 
are compared, and the proportion (%) is calculated. [19] The procedure 
described is the indirect proportion method. If the specimen is decided to 
contain enough bacilli after microscopy, it can also be used for a direct 
resistance test. The advantage of the direct test is that the result can be 
available after about three weeks when utilizing the direct agar proportion 
method. There are other modifications of the proportion test such as using 
agar plates instead of the egg-based Löwenstein-Jensen medium. [19] 
 
4.3.7 Liquid Media for Culture and Drug-Susceptibility Testing 
In many industrialized countries liquid media are used in laboratory 
diagnostics of TB. The WHO recommends a step-wise approach to the use 
of liquid medium for low- and middle-income countries, but only with a 
simultaneous strengthening of laboratory capacity in the countries. [20] The 
BACTEC method is based on the radiometric detection of growth. 
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Consumption of 14C-labeled carbon and production of radiolabeled CO2 by 
growing bacteria is measured and recorded. The result can be available after 
about three weeks. During this time both isolation of mycobacteria and the 
susceptibility testing are done. The major disadvantages of this method are 
the production of radioactive material and the high costs. [19] Because of 
this, together with the complexity and demand of trained human resources, 
this method is difficult to implement in many countries where the need for 
such a rapid test is most present. [17] 
 
Other systems for culture on liquid media, developed to avoid the problem 
with radioactive disposal, are MB/BacT, the EFP Myco System and 
Mycobacteria Growth Indicator Tube among others. [19] 
 
 
4.4 Detection of Latent Tuberculosis Infection 
4.4.1 The Mantoux Test 
The Mantoux test is an unspecific test that reveals if the patient has been 
exposed to mycobacteria. It is the most used form of tuberculin skin test in 
the world. The tuberculin used in skin tests today is purified protein derivate 
or PPD. This form tuberculin was first made in the 1930s. Tuberculin 
consists of different proteins processed from a liquid culture of M. 
tuberculosis. The standard for tuberculin used in the Mantoux test is called 
PPD RT 23 and is kept in Statens Serum Institut in Copenhagen. [10] PPD 
RT 23 exists in two different compositions of tuberculin units (TU), 2 
TU/0,1 mL and 10 TU/0,1 mL which contain 0,04 micrograms and 0,2 
micrograms of Tuberculin PPD RT 23 respectively. 2 TU/0,1 mL is the 
recommended composition, unless low tuberculin sensitivity is expected. 
[21] 
 
When performing the Mantoux test, the standard dosage of 0,1 mL 
tuberculin containing 2 TU is injected intradermal in the middle third of the 
forearm. After a successful injection, a papule of 8-10 mm in diameter will 
appear and then disappear in about ten minutes. [10] The result of the test is 
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seen after 48-72 hours, when the size of the induration is evaluated. The 
induration is often flat, uneven and surrounded by an area of redness. [21] It 
is measured transversely on the long axis of the forearm. An induration of 0-
5 mm is considered negative, 6-14 mm is considered positive and 15 mm or 
more is considered strongly positive. A positive test can indicate either 
infection with the M. tuberculosis complex, infections with non-tuberculous 
mycobacteria or that the person has been immunized with the BCG vaccine. 
Individual risk factors, national guidelines and epidemiological factors must 
always be accounted for when interpreting the result. [10] 
 
In some countries the Mantoux test is used not just for diagnostics, but also 
to verify immunization by BCG vaccine or to ensure that only persons who 
have not been exposed to M. tuberculosis are vaccinated. [21] When a 
person has symptoms of TB, further diagnostic procedures should be 
performed regardless of a Mantoux test results. 
 
The major problems about the Mantoux test is the low sensitivity in 
immunosuppressed persons, and the influence on the test of the BCG 
vaccine and prior infections with non-tuberculous mycobacteria. [14] Old 
age and severe infection can also give a false negative test result. [10] 
Nevertheless the tuberculin skin test was the only method of identifying 
infection with M. tuberculosis in persons with latent TB infection just 10 
years ago. [22] In settings where it is possible to treat persons with latent 
TB infection it is therefore important to detect these individuals. 
 
4.4.2 Interferon Gamma Release Assays (IGRAs) 
During the last ten years, two new blood tests for detecting latent TB 
infection have been developed. [23] In these tests interferon-γ secretion 
from T-cells is measured after exposure to the antigens ESAT-6 and CFP-10 
that are specific for the M. tuberculosis-complex. Secretion of IF-γ indicates 
either latent or active infection, but is not suitable to distinguish the to states 
of infection. [24] Because the antigens used are not present in neither the 
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BCG vaccine or in most non-tuberculous mycobacteria, these tests are more 
specific than tuberculin skin tests. [23] 
 
There are two different tests, the QuantiFERON TB-Gold (QFT) and the T-
SPOT-TB. The QTF is an enzyme-linked immunosorbent assay (ELISA), 
where the IFN-gamma concentration is measured. The T-SPOT-TB is an 
enzyme-linked immunospot assay (ELISpot) counting the T-cells releasing 
IFN-gamma. In the ELISA there is an additional antigen to ESAT-6 and 
CFP-10, namely TB 7.7. [23] Both the T-SPOT-TB and the QFT have 
shown higher sensitivity and specificity than tuberculosis skin testing TST 
like the Mantoux test. In many countries they are already a part of the 
national guidelines for detecting latent TB.  
 
One of the drawbacks with the interferon gamma release assays is that they 
appear more expensive than tuberculin skin tests, although analyses have 
shown that they are cost-effective because the numbers of persons treated 
unnecessary with chemoprophylaxis is reduced. [23] As already mentioned 
they cannot be used to differentiate between active and latent TB, neither for 
treatment nor for monitoring. The use of IGRAs in detecting latent TB is a 
method still in progress, and already an important diagnostic tool for latent 
TB in many countries. 
 
 
4.5 Treatment of Tuberculosis 
4.5.1 First-line anti-tuberculosis drugs 
There are four key first-line anti-tuberculosis drugs: 
• Isoniazid (H) 
o The major components of the envelope of M. tuberculosis are 
mycolytic acids, significant evidence supports the theory that 
isoniazide blocks the syntheses of these acids, however its 
actions are complex. [25] 
• Rifampicin (R)  
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o Inhibit bacterial DNA-dependent RNA polymerase, and 
appears to result from the drug binding in the polymerase 
subunit within the DNA/RNA channel and directly block 
elongating of RNA. [26] 
• Pyrazinamide (Z) 
o A synthetic analogue of nicotinamide, but the mechanism is 
not fully understood. [27]  
• Ethambutol (E)  
o The actions of ethambutol are not completely known. It 
targets the mycobacterial cell wall, which consists of an outer 
layer of mycolic acids bound covalently to peptidoglycan via 
the arabinogalactan.  Ethambutol inhibits polymerization of 
cell wall arabinan, and this result in accumulation of a lipid 
carrier. Hence the drug interferes with transfer of arabinose 
to the cell wall acceptor. [28] 
 
Streptomycin (S) acts by inhibiting bacterial protein synthesis. It is defined 
by WHO as a first-line anti-tuberculosis drug, [27] but the standard regimen 
for treating new TB patients presumed to have drug-susceptible TB does not 
include Streptomycin. It is however used in special cases; such as certain 
forms of extrapulmonary TB and in the treatment of multi drug resistant TB. 
 
4.5.2 Combining First-Line Drugs for Effective Treatment  
Several anti-tuberculosis drugs must be given together in order to cure a 
TB-patient, and the use of any of these as mono-therapy leads to selection of 
resistant strains.  
 
A patient with TB is inhabited by different bacillary populations: 
• Metabolically active bacilli inside lung cavities, which replicate 
constantly and rapidly. 
• Bacilli situated inside macrophages. These replicate slowly due to 
lack of oxygen and the acidic pH in the cytoplasm they live in. 
Dormant bacilli are metabolically inactive; they replicate very 
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slowly, but can start to multiply as soon as the immune defense 
system weakens. [4] 
 
Isoniazid (discovered 1952) and rifampicin (discovered 1957) are the most 
effective bactericidal drugs, and work both against rapidly multiplying 
bacteria, and also semi-dormant bacilli inside the macrophages. [4, 29, 30]   
 
Pyrazinamide (discovered 1952) destroys intracellular bacteria that live in 
an acid environment. Streptomycin (discovered 1943, soon after penicillin) 
is active only against extracellular bacteria, as it cannot penetrate the cell 
membrane. These are of medium efficacy. [4, 31, 32]   
 
To prevent emergence of resistant bacilli Ethambutol (discovered 1961) is 
used in conjunction with bactericidal drugs. Ethambutol is much less 
effective as it is bacteriostatic.  
 
Rifampicin and pyrazinamide are the only medications that have a 
sterilizing action as it destroy persistent bacilli, and they are always used in 
short-course chemotherapy. [4] 
 
4.5.3 Second line drugs 
There are two major indications for the use of second-line therapy: 
• Resistance to first line drugs. 
• Patient intolerance to first-line drugs.  
 
A parenteral aminoglycoside (streptomycin, kanamycin, amikacin, 
capreomycin) and a quinolone (levofloxacin, moxifloxacin) are 
recommended added when treating MDR-TB. These are usually given for 6 
months and cure rates are high for regimens that include them. Treatment 




4.5.4 Treatment Categories Recommended by the WHO 
• New cases of smear positive TB – defined as a patient who has 
never previously been treated for TB or who has received treatment 
for less than one month. 
• Cases who have already received treatment for at least one month in 
the past who need re-treatment: 
o ”Relapses” – Smear examinations are again positive after the 
patient having been treated and declared cured earlier. 
o ”Failures” – Smear examinations have remained positive or 
become positive once again five or more months after 
starting treatment. 
o ”Return after interruption” – Patients who return smear-
positive after interrupting treatment for more than two 
consecutive months. 
• Chronic cases defined as smear-positive cases of pulmonary TB who 
have already received a supervised re-treatment regimen. [4] 
 
4.5.5 Monitoring the efficacy of treatment 
Efficacy of treatment is measured by examination of sputum smears 
performed at following stages of treatment (in the case of pulmonary TB): 
• Sputum conversion is observed at the end of the initial phase, and 
this phase should be prolonged by one month of the patient is still 
smear-positive. 
• At the end of the 4th month for 6-month regimens, and at the end of 
the 5th month for 8-month regimens. 
• During the last month. 
 
In the case of extrapulmonary TB, follow-up is essentially clinical. A 




4.6 Drug resistance  
The ability to survive the presence of a drug that normally kills or inhibits 
growth is known as resistance. Resistance is a phenotype. It is caused by 
mutation, and cannot be regarded the same as tolerance; a conditional 
phenotype mediated by the physiological state of the bacilli. [34] If a 
bacterium lacks a susceptibility target and is impermeable to an antibacterial 
agent, this is known as innate resistance. [27] 
 
The MIC (minimal inhibitory concentration) of a drug is defined as the 
minimum concentration of the drug that kills 99% of cells. [34] 
 
4.6.1 Drug resistance mechanisms 
Drug-inactivating enzymes, drug extrusion mechanisms, target 
modification, target overexpression and barrier mechanisms are some of the 
resistance strategies bacteria develop. [34] 
 
M. tuberculosis and other mycobacteria have several strategies of innate 
resistance, which make them a challenge to medicine and the 
pharmaceutical industry, amongst other reasons because: 
• They are difficult to penetrate with antibiotics due to a waxy outer 
layer. 
• Inhibition takes weeks or months to achieve as a result of extremely 
slow multiplication, and long-term therapy is therefore a challenge 
for drug delivery. Orally administrable drugs are desirable. 
• Antibiotics have difficulties reaching the bacteria as they are 
localized intracellular, and the cells are surrounded by a caseous 
mass. [27] 
• Recent reports have suggested that efflux pumps may also be 
involved. [29] 
 
Spontaneous genetic mutations result in development of resistance in M. 
tuberculosis. This phenomenon is amplified due to use of drugs. 
Spontaneous chromosomal mutations happens at a frequency of 10^6 to 
 23 
10^8. The probability of mutations against both isoniazide and rifampicin is 
10^4, and is not that uncommon in pulmonary TB, as there are huge 
amounts of bacteria involved. [27] If you treat an infected patient with 
mono-therapy, the majority of bacilli will die, but the resistant mutant will 
survive and multiply and cause a bacterial population dominated by the 
resistant strain. Acquired resistance to one or several drugs is caused when 
further mono-therapy by another drug is given and the mutant bacteria also 
resistant to the second drug are selected. [35] 
 
Primary resistance is a term used regarding a patient whose disease is 
caused by a strain that is resistant to an antibiotic, and has been infected 
with it by another patient. This patient with primary resistance may have 
never received the drug in question. [4] 
 
In other mycobacteria and bacteria you might find mutations caused by 
mobile genetic elements such as plasmids, but mutations in the genome of 
M. tuberculosis is always a result of mutations in the chromosomal DNA. 
[35] M. tuberculosis does not possess plasmids. [29] 
 
Resistance to rifampicin and isoniazid is defined as multidrug resistant 
tuberculosis (MDR-TB). MDR in addition to a fluoroquinolon and 
resistance to at least one of three injectable second line-tubercular drug i.e. 
amikacin, kanamycin and/or capreomycin is known as extensively drug 
resistant tuberculosis (XDR-TB). [36] This requires the use of multiple 
second-line drugs and potentially surgery. [29] 
 
4.6.2 Development of resistance 
There are several factors contributing in the development of resistance. 
• Genetic factors: Accumulation of changes in the genomic, content, 
spontaneous mutations, etc.  
• Inadequate treatment is an important factor; use of a single drug to 
treat, the initiation of an inadequate regimen using first line anti-TB 
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drugs, addition of a single drug to a failing regimen and variations in 
bioavailability of any anti-TB drugs predispose for MDR.  
• Inadequate treatment adherence: Non-adherence is related to 
psychiatric illness, drug abuse, homelessness and alcoholism.  
• Also factors such as poor administrative control on purchase and no 
proper mechanism on quality and bioavailability tests. [36] 
 
The specific molecular mechanisms for resistance to some of the anti-
tuberculosis drugs are mentioned in figure 3 (Antituberculosis drug and 




5 Tuberculosis as a global health problem 
5.1 Changes in the Tuberculosis Situation During the 20th Century 
 
Tuberculosis has existed for several thousand years. There was an increase 
of the disease in the 19th century lasting until the living conditions 
improved in the 20th century. The cause of the disease was discovered by 
Robert Koch in 1882 when he distinguished the M. tuberculosis from M. 
bovis. The tuberculin tests were available from 1890, and the Bacillus 
Calmette-Guérin (BCG) vaccine was used in humans for the first time in 
1921 but became widely used in 1945. At the same time the first 
medications were used in treatment. [37] Despite the early known 
diagnostic tools and the existence of the vaccine, TB is still a global 
challenge. 
 
After the global prevalence of TB had been falling for decades towards 
1980, the situation changed. [38] An increase in incidence cases was 
notified both in Europe and the USA. The main explanation was the 
increased immigration to these regions. The decrease in TB prevalence in 
Europe and the USA during the 20th century had not been followed to the 
same extent in low-income countries. Two other factors were influencing 
the TB situation; the economical crisis in the former Soviet Union led to an 
increase in TB in this part of the World, and resistance became a bigger 
problem. Secondly, in the sub-Saharan African countries, the HIV epidemic 
was growing followed by an increase in TB. [38] 
 
This quite sudden change in the global TB situation, also affecting Europe 
and the USA, led to a refocus of the international attention on TB. [38] 
 
Between 1997-2000 there was an increase in global incidence rates by 0,4% 
per year. In 1997 the estimated global incidence rate for TB was 136/100 
000. [39] The highest incidence was in WHO Region of Africa with 
259/100 000 mostly due to high incidence rates in sub-Saharan African 
countries. In 2000 the incidence rate of TB in the same area was 293/100 
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000. The estimated TB burden measured by incidence for the Russian 
federation was 106/100 000 in 1997. [39] At this point, the growing TB-
burden could be explained mainly by the simultaneously growing HIV 
epidemic, 8% of new cases were associated with HIV infection in 1997. 
[39] At the same time the problem with MDR in some countries was 
growing, among them Russia. [40] 
 
5.2 The Current Tuberculosis situation 
 
The situation today is described in the WHO report from 2010 Global 
Tuberculosis Control. [41] 
 
Since 1997, the WHO has published an annual report on the global TB 
status. The latest report from 2010 contains numbers describing the TB 
epidemic up to 2009. According to this report the estimated global burden 
can be illustrated by the 14 million prevalent cases, 9,4 million incident 
cases, and 1,3 million deaths due to TB (excluding deaths among HIV 
positive cases). [41] 
 
The global incidence rate of 2009 was 137/100 000, showing a slow 
decrease since the peak at 140 /100 000 in 2004. In 2000 the incidence rate 
was estimated 136/100 000. The highest incidence rate from 2009 was in 
the African region, estimated 345/100 000. For comparison the WHO 
numbers from 2000 show an incidence rate of 314/ 100 000 for this region, 
demonstrating an overall increase in this region the last ten years, again with 
a slow decrease after a peak in 2004. In Russia, the rate was 106/100 000 
and has been quite stable the last ten years. Figure 1 illustrates the estimated 
TB incidence rates by country for 2009.  
The treatment success rate of smear-positive cases has been increasing 
globally from 1995 (being 57%) to 86% in the cohort from 2008. Treatment 
success rates are however lower in the European Region, 66%. [41]  
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The highest numbers of MDR-TB in 2009 were notified by countries in the 
European region and in South Africa. The numbers are increasing and 
expected to increase even more towards 2015. 
 
The Millennium Development Goal (MDG) regarding TB is to halt and 
reverse the incidence of TB by 2015. In addition, the Stop TB Partnership 
has set targets including halving the TB prevalence and death rates by 2015 
compared to the levels in 1990. The MDG target can be reached if the 
current decrease of incidence rates of about 1% per year continues. The 
halving of mortality at a global level is still possible whereas halving the 
prevalence by 2015 seems to be out of reach. Some of the targets have 
already been reached in certain regions, like the prevalence in the Region of 
the Americas, which is already halved compared to 1990 levels. With the 
same progress as the last years, this target can be reached in the other 
regions as well, except the African region and the South-East Asian Region 
where it seems out of reach. Mortality rates are falling in all regions, and 
can be reached in all regions except the African region. Halving mortality 
before 2015 is still possible for some of the high burden countries, among 
them Russia. [41] 
 
The trends in TB incidence, prevalence and mortality rates follow 15 years 
of international contribution in the fight against TB. This includes 
implementing the DOTS strategy from 1995 followed by the Stop TB 
Strategy from 2006. 41 million TB patients have been treated successfully 
by DOTS programs between 1995 and 2009. There are still some important 
challenges to overcome, including one-third of incident TB cases not being 
reported to be treated in DOTS programs, only 10% of patients with MDR-
TB being diagnosed and treated according to international guidelines, 
missing TB status among HIV positive persons and HIV status among TB 
patients and funding gaps which are still large despite an increase in funding 
the last ten years. [41] 
 
In 2009 an estimated 1,1 million of the incident TB cases were HIV-
positive. This makes up 12% of all incident cases, illustrating the existing 
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challenge of HIV/TB co-disease. [41] 80% of these HIV positive cases were 
in the African Region [41] The risk of developing TB is 20 times higher in a 
HIV infected person than in a person not infected with HIV.  [42] TB is an 
important cause of death amongst HIV infected people. The WHO 
recommends intensified TB case findings, isoniazid preventive therapy and 
infection control for TB to reduce the burden of TB among HIV positive 
persons. [43] Figure 2 illustrates the estimated HIV prevalence in new TB 
cases by country for 2009. 
 
 
5.3 Strategies in Anti-Tuberculosis Work 
 
From the 1990s the growing global challenge of TB led to the development 
of programs and other actions in TB control. A new system for global TB 
surveillance was implemented by the WHO, making the annual reports and 
strengthened control of the international TB situation possible. There was 
also an increased focus on resistance. Several foundations consisting of 
nations, non-governmental organizations, and private persons were, and still 
are, important in the process. The International Union Against Tuberculosis 
and Lung Disease, the Stop TB Partnership, The Global Fund to Fight 
AIDS, Tuberculosis and Malaria, A Global Drugs Facility and the Green 
Light Committee are examples of such foundations important in different 
areas of fighting the TB challenge. [38] Implementation of DOTS an later 
the Stop TB Strategy have, as already mentioned, been essential for the 
work against TB, [41] and will be shortly described.  
 
5.3.1 DOTS 
Directly observed treatment short course, DOTS, has been the core in 
controlling the global TB situation the last years. It was launched by the 
WHO in 1995 and 41 million patients have been treated according to this 
strategy. [8] DOTS has five main components:  
• Political commitment with increased and sustained financing 
• Diagnosis made from bacteriology. 
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• Standardized treatment with supervision and patient support. The 
treatment should be followed closely to avoid interruptions.  
• An effective drug supply and management system. There should be 
national systems to assure a continuous drug supply to the 
institutions where treatment is given. Drugs should be free, both to 
decrease the expenses for each patient and because individual 
treatment has a preventive effect on TB in the society. 
• Monitoring and evaluating system and impact measurement. The 
recommendations include establishing a reliable monitoring and 
evaluation system that facilitates communication between different 
levels of the health system. The system should be the same in all 
levels of the health system as well as in all parts of the country, and 
between countries, so that local and national conditions regarding 
TB can be identified. [44, 45]  
 
5.3.2 The Stop TB Strategy 
In 2006 the new Stop TB Strategy was introduced by the WHO. It is 
essential on the way of achieving a significant reduction in the global 
burden of TB according to the Millennium Development Goal and the 
targets of TB control set by the Stop TB Partnership. [45] The Stop TB 
Strategy is based on DOTS and has six components.  
• Pursue high-quality DOTS expansion and enhancement. 
• Address TB/HIV, MDR-TB and other challenges. Co-infection with 
HIV and TB has become a big challenge. The HIV epidemic gives 
good conditions for the TB epidemic, and collaboration in actions 
against HIV and TB is necessary in the approach to this problem. 
One of the other challenges to be addressed is the increasing MDR-
TB incidence. Guidelines considering MDR-TB specifically are 
developed, the DOTS-plus. 
• Contribute to health system strengthening. This is because 
strengthening of health systems is important for fighting any disease, 
TB makes no exception. A well functioning health system is 
especially important when it comes to diseases demanding a long-
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term follow up and treatment such as TB. Therefore the Stop TB 
Strategy encourage TB programs and partners to participate in 
efforts to improve actions across all major areas of health systems, 
including policy, human resources, financing, management, service 
delivery, and information systems.  
• Engage all care providers. This means involving health care-
providers outside the public health care in standard case-finding 
procedures to avoid delayed diagnosis, wrong diagnosis and 
incomplete treatment. 
• Empower people with TB, and communities. This includes involving 
the communities in the fight against TB by more information, better 
communication between the communities, current and former TB 
patients and the health care providers and financial and social 
support of TB patients.  
• Enable and promote research. The last of the six components of the 
Stop TB Strategy is about the importance of research, both regarding 
effectiveness of different approaches to TB care to identify problems 
and find solutions, and regarding the development of new 
diagnostics and vaccines. The Stop TB Partnership´s Working group 
should be supported in this work by countries.
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6 The Case of Russia and the Growing Epidemic of 
Multi-Drug Resistant Tuberculosis 
6.1 A Historical Perspective on Tuberculosis in Russia 
6.1.1 The Tsar Regime and The Russian Revolution 
From 1613 to 1917 Russia was ruled by the Romanov dynasty. [46] In the 
work ”The House of the Dead” (1861) by author Fyodor Dostoyevsky 
(1821-1881) he described everyday life in a Tsarist prison confirming that 
TB in prisons is not a new phenomenon. [47] At the time TB outside the 
prisons also was a huge problem.  
 
Following the revolution there were upheavals that led to increased risk of 
TB, and the early Soviet state established a nationwide network of anti-TB 
institutions. TB care was even organized in the prison camps of Stalin’s 
gulag, where millions of people met their deaths. [47] 
 
6.1.2 The Soviet Union 
Mortality of TB before World War 1 was 400/100 000. While 1,7 million 
Russian soldiers were killed in war, 2 million civilians died from TB. [47] 
By the end of the 1950s, drug therapy had been introduced in most 
developed countries, and this reduced the need for sanatoria beds. All but 
the sickest patients could be treated at home, without the need for a hospital 
bed. [48] These changes were not introduced in the Soviet Union. The 
soviet states based the treatment on isolation, sanatoria, X-ray diagnosis and 
sometimes surgery. Medical personnel wanted it to continue this way, as 
they depended on it to keep their jobs, due to the existence of TB beds in 
hospitals and the carrying out of operations. A move to the DOTS system 
was considered a threat and a personal defeat; they had believed in their 




6.1.3 Dissolution of the Soviet Union 
In 1989, at the end of the Soviet regime, the TB rate was 44.7/100 000. Nine 
years later (1998) the numbers in Russia had increased to approximately 
100/100 000. The main cause of this increase was the sudden poverty that 
affected millions of people, and thus caused a dramatic reduction in living 
standards. [47] 
 
Approximately 50 million people lived on less than 15 US$ per day. As a 
consequence vegetables were unavailable, fruit and meat was used less and 
less as an element of the diet in the 1990s. Earlier, during Soviet regime, all 
land and buildings belonged to the state. By the early 1990s waiting lists 
prior to receiving own housing were not uncommonly more than 10 years. 
20% of families in the urban areas lived in small apartments, or shared their 
space with one or several other families. This is an important factor in the 
spread of TB. [49] In addition, millions lost their jobs, and no longer had 
welfare and health services that had been provided by their work place, 
including TB screening. The work places also had contributed with 
sanatorias where people could stay in their jobs during treatment. This 
meant that TB rates were on the rise due to social problems, while the TB 
control systems no longer worked as they should. [47] 
 
In the 1990s the health care system were massively criticized by the mass 
media, where they warned the population about the more adverse effects of 
the TB drugs and hazards of X-ray examinations. This led to the people 
being skeptical of using medicine, and regarding radiation safety. This was 
increased after the Chernobyl nuclear accident, and traditional screening 
based on fluorography declined. [49] 
 
6.1.4 Tuberculosis in Prisons of Post-Soviet Russia 
Prisons became the site of an epidemic. [47] Russia has an enormous prison 
system, including ~0.7% of the current population, which is nearly 1 million 
inmates. [50] As living standards were reduces outside prisons, they were 
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reduces parallel on the inside, in a population composed primarily by the 
homeless and poorest in society. [47] 
 
As a heritage from the Tsar regime, the prisons system in both Russia and 
the Soviet Union were based on banishment and hard labor in prison camps. 
A prison would hold thousands of prisoners, which slept in huge dorms. 
Work was usually in mines or factories, and bad work conditions kept 
others than prisoners from taking such jobs. After the end of the Soviet 
Union, Russia had the second highest rate of imprisonment, holding 678 
inmates per 100 000 population. [47] 
 
In some regions the prevalence of resistance to at least one drug among new 
cases was 35-44%, and the mortality associated with TB in Russian prisons 
were 171 deaths per 100 000 prisoners. [50] 
 
The prisons became so crowded that prisoners died from suffocation. They 
lacked beds and had to sleep in shifts. Kresty prison in St. Petersburg held 
10 000 inmates in a prison constructed to keep 3000.  
 
The prisons no longer had the state as an employer, and factories and mines 
closed. There were no longer work available in the prison camps, and 
therefore they had no income. Building deteriorated and food quality was 
reduced drastically. [47] Close to every prisoner was exposed to TB, and 
thousands of infected ex-convicts were released into the general population 
every year. In 1995 TB cases among prisoners were finally included in 
official statistics, and revealed a concentration in the penalty system. [51] A 
treatment program was established in the central prison in Baku, Azerbaijan, 
and the medical director of a Siberian prison asked Médicins Sans 
Frontières for help. The next year DOTS was introduced. In 2008 three non-
governmental organizations stated that nearly 100 000 prisoners had active 
TB disease, and 20 000 of these were drug resistant. [47] 
 
Late diagnostics, lack of isolation, inadequate treatment of those who are 
contagious, high turnover of prisoners, overcrowding and poor ventilation 
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are listed by the WHO among a number of reasons that contribute to the 
spread of TB. Poor nutrition, physical and emotional stress worsens the 
situation. It is also estimated that HIV is 75 times more common in prisons 
than in the outside community. [47] 
 
 
6.2 Multi-Drug Resistant Tuberculosis in a Global Perspective 
 
Resistance of M. tuberculosis to antibiotics appeared shortly after the 
introduction of the first anti-TB drugs in the 1940s and 1950s. To begin 
with, resistance in mycobacteria was mostly to isoniazid, streptomycin and 
p-aminosalicylic acid (PAS). Combination-therapy to prevent resistance was 
established, so was reliable techniques for testing mycobacteria for 
resistance to anti-TB drugs. MDR-TB was rare. [52] With the discovered 
outbreaks of MDR-TB in some European countries and the USA in the late 
1980s, especially among HIV-positive persons, attention was again drawn 
to TB and resistance. [53] 
 
An estimated 440 000 cases of MDR-TB emerged globally in 2008. [52] 
This constitutes 3,6% of the total amount of new TB cases that year. 27 
countries are considered high MDR-TB burden countries, among them 
China and India, which together account for almost 50% of the estimated 
global number of incident MDR-TB cases, and Russia. In 2008, 150 000 
deaths due to MDR-TB were estimated bye the WHO report, including 
those with HIV infection. Resistance to second-line anti-TB drugs is also a 
growing problem. 963 cases of XDR-TB were reported to the WHO in 
2008. The actual number is probably higher because of insufficient 
laboratory capacity of drug-susceptibility testing on second-line drugs. The 
proportion of XDR-TB among MDR-TB cases is thought to be 5,4%. [52] 
 
As described in the WHO report, [52] the major challenges regarding MDR-
TB are the lack of drug susceptibility testing to detect MDR-TB among 
previously treated cases where the probability of MDR-TB is greater, and in 
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the availability and costs of treatment of MDR-TB, which is 50 to 200 times 
higher than for a drug-susceptible TB patient. Different establishments have 
been important for treating MDR-TB, supporting treatment of patients 
directly. The EXPAND-TB Project was created because of the lack of 
resources in many countries to improve the laboratory capacity to diagnose 
MDR-TB. This is an initiative with several partners including the WHO, the 
Global Laboratory Initiative, the Foundation for Innovative New 
Diagnostics, the Stop TB Partnership through Global Drug Facility and 
UNITAID, working for access to MDR diagnostics in 27 countries. 60% of 
patients that received treatment from MDR starting in 2006 were cured 
overall. Even in well-resourced settings the overall treatment-success MDR-
TB patients remains low. [52] 
 
6.2.1 The Beijing Strain 
One type of mycobacteria, the Beijing genotype family, has been coupled to 
a tendency of higher degree of virulence and resistance. The strain was first 
described in 1995, [54] when it was found to be the dominant strain of M. 
tuberculosis in China and some of the neighbor countries. It was 
characterized by the pattern of the repetitive DNA sequence IS6110, and 
further by IS6110-associated restriction fragment length polymorphism 
(RFLP). A high degree of similarity in the IS6110 RFLP patterns showed 
that the strains from China and neighboring countries were part of the same 
"family" or genotype.  
 
Later, spacer oligotyping, or spoligotyping was described. This method 
makes use of polymorphism in the direct repeat region of the genome, with 
different number of short direct repeats separated by non-repetitive spacers. 
[55] Other methods for genetic differentiation are also used today.  
 
Since 1995, strains from the Beijing family have been reported from several 
countries, not infrequently related to MDR-TB. [56] Because strains from 
the Beijing family show more homogeneity than strains from other genotype 
families, the hypothesis of selective advantages was formed. Several 
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subgroups of Beijing family strains exist, among them the W-strain. This 
strain first emerged in New York City mostly among HIV positive inmates 
and hospitalized patients and showed a high degree of multi-resistance. The 
Beijing family is dominating in East Asian countries, representing about 
50% of the strains in this area and about 13% of the strains globally.  
 
The causes of dissemination of strains from the Beijing family are not 
certain. Some studies on animal models have shown that BCG vaccination 
is less protective against infection with strains from this family, [57] while 
others have not. [58] Increased transmission of Beijing strains is another 
hypothesis of dissemination. In a study from Arkhangelsk oblast in the 
Russian Federation this was indicated by a high rate of clustering among 
strains belonging to the Beijing genotype. [59] An increased virulence 
among Beijing strains is also one of the hypotheses of this genotype 
becoming more frequent. [56] 
 
Drug-resistance is shown to be associated with these strains in several 
studies. There are three main hypothesis of how to explain this; it can be 
due to a higher rate of mutations in these strains. Secondly the cell- wall 
structure of these bacteria, which can influence intracellular concentration 
of drug in the bacteria, can be an explanation. Lastly, an increased virulence 
demanding a prolonged time of treatment and sometimes use of several 
different drugs can make the development of resistance more probable. [56] 
 
Finally, the various factors can have different roles in spread of strains of 
the Beijing genotype in different settings. [59] 
 
 
6.3 Drug resistance in Russia 
6.3.1 The Present Situation in Arkhangelsk Oblast 
The Arkhangel oblast is situated in the northwestern part of Russia, a 
country with a population of 141 millions in 2009, and a high burden of TB 
with an incidence rate of 106/100 000 the same year. [60] In the 
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Arkhangelsk oblast there are 26 municipal districts and 26 TB coordinators. 
They all report to the central Antituberculosis Dispensary in Arkhangelsk 
city. TB-activities in the Arkhangelsk oblast have been according to WHO 
recommendations for more than 10 years. There is a well functioning 
system for monitoring the spread of drug resistance and drug susceptibility 
testing has been performed since 2004 in the central laboratory. [61] 
 
Fresh numbers from the Arkhangelsk oblast show a decrease in TB-
incidence (counting both new cases and relapses) over the last ten years, 
sinking from 118,7 per 100 000 population in 2001 to 64,7 per 100 000 in 
2010. [61] Despite the decrease in incidence there are still many challenges 
considering the TB-situation in this area. The proportion of MDR among 
new cases is increasing. In 2001 the number of MDR-TB cases constituted 
10 % of new cases, compared to 33,9 % in the first three quartiles of 2010. 
Among retreatment cases, the percentage was as high as 72,5 % in the first 
three quartiles of 2010. [61] The absolute numbers of new MDR-TB cases 
have actually been quite stable since 2005. The increasing proportion of 
MDR among new cases can partly be explained by the decrease in the total 
number of new TB cases.  
 
XDR have also been detected in Arkhangelsk oblast, 9 cases were registered 
in 2010. [61] The treatment of this form of TB is difficult because the drugs 
in use are less potent, more toxic and a lot more expensive than the regular 
drugs. [62] 
 
6.3.2 Resistance in Russia – The WHO Estimates from 2010 
In Russia as a whole, the estimated proportion of MDR among new TB 
cases was 15,8% overall, in the WHO report from 2010. This estimate 
builds on subnational drug resistance data. On subnational level, as high 
proportion as 28,3% MDR-TB among new cases was reported from 
Murmansk Oblast to WHO in 2007-2008. Two other oblasts in the 
northwestern region of Russia also had proportions higher than 20% MDR 
TB, namely the Arkhangelsk Oblast and Pskov Oblast, with 23,8% and 27, 
 38 
3% MDR-TB among new cases respectively. The proportions are of course 
even higher among previously treated cases: 35,7% in Murmansk Oblast, 
58,8% in Arkhangelsk Oblast and 50,0 in Pskov Oblast. 5,4% was the 
lowest proportion of MDR-TB among new cases reported from a Russian 
oblast. [52] This demonstrates the importance of a continuous focus on 
MDR in this region.  
 
There are already established well-organized systems for surveillance and 
reporting of MDR- and XDR-TB in parts of Russia. 12 oblasts are included 
in the group of countries and regions providing class A continuous drug 
resistance surveillance data according to the WHO report. This means that 
certain conditions are met, including a "detection rate of at least 50% for 
new cases, positive culture available in at least 50% of all notified cases, 
drug susceptibility testing (DST) results available in at least 75% of all 
culture positive cases, accuracy of at least 95% for isoniazid and rifampicin 
in the most recent DST proficiency testing exercise with a supranational 
reference laboratory". [52] In fact, all the 12 oblasts report a case detection 
rate of 85% and DST coverage of between 87-100%.  
 
6.3.3 Special Features of the Tuberculosis Epidemic in the Northwestern 
Region 
In a study from Murmansk of collected isolates from culture positive cases 
during 2003 and 2004, the prevalence of MDR-TB was 26% among new 
cases and 72,9% among previously treated cases. Spoligotyping of the 
isolates from new MDR-TB cases were performed, revealing that 79,8% 
belonged to the Beijing family, more specifically the SIT1 genotype. In total 
44% of the samples, both susceptible and resistant, belonged to the Beijing 
family. [63] The study also indicates a considerable ongoing transmission of 
MDR-TB in the society. A study from Arkhangel Oblast on isolates from 
patients with pulmonary TB from 1998 and 1999, showed similar 
proportions of samples belonging to the Beijing strain family, 44,5%. This 
study also demonstrated that the proportion of multi-drug resistance is much 
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higher within strains from the Beijing family (43,4%) than other strains 
(10,6%). [59]  
 
The high prevalence of the Beijing family in this part of Russia was again 
confirmed in a study published in 2009 of 176 isolates from Arkhangelsk 
Oblast, Murmansk Oblast, the Public of Karelia and the public of Komi. 
[64] The genetic diversity among the isolates and drug susceptibility were 
investigated. 47,1 % of the strains belonged to the Beijing family. However, 
there was a significant difference in prevalence of the strains between the 
oblasts, the Arkhangelsk and Murmansk oblast having the highest 
proportion of Beijing strains. The Beijing genotype was significantly 
associated with resistance to all first-line anti-tuberculosis-drugs, and also to 
the second-line anti-tuberculosis-drug ethionamide. The proportion of 
clustered isolates was higher among strains from the Beijing family, 
indicating more transmission of these strains. 
 
6.3.4 Risk Factors for Tuberculosis in the Northwestern Region 
Several factors are pointed out as possible explanations on the MDR-status 
in the northwestern part of Russia, and Russia as a whole. The economic 
collapse following the dissolution of the Soviet Union had a great impact on 
the health of the Russian people in general. [65] There was a decrease in 
financial support to medical institutions, leading to deficient diagnosis and 
treatment of TB. The Soviet TB-control program relying on chest X-ray, 
vaccination and long-term hospitalization for treatment was partly continued 
after the dissolution. [65] Lack of capacity for sputum examination and drug 
susceptibility testing was one of the factors delaying an approach more 
similar to the recommendations from the WHO. [66] An inadequate drug 
supply led to treatment with separate drugs, [66] this again possibly 
contributing to development of resistance. [63] Then, when resistance 
developed, after a while representing a significant proportion of cases, and 
the capacity of diagnostics and treatment was insufficient, transmission of 
MDR-TB became a big problem. [66] Patients not completing treatment is 
another problem contributing to development of resistance, like in 
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Murmansk. [63] In some parts of Russia the HIV epidemic is also growing 
and has given rice to the problem of MDR-TB and HIV co-infection. [63] 
 
Risk factors for infection with drug-resistant M. tuberculosis were 
investigated in another study from Arkhangelsk Oblast, revealing significant 
association between drug-resistance and female gender, previous TB 
treatment and interruption of ongoing treatment. [66] The same associations 
were significant for MDR specifically. 
 
In many parts of the world, there is a high prevalence in prisons of both TB 
in general and drug-resistant TB. This is due to conditions that facilitate 
growth and transmission of the bacteria such as inadequate ventilation, 
overcrowded institutions and poor health of inmates. In Arkhangelsk, a 
study from 2001 revealed that MDR among new cases in prison were 2,5 
times higher than in community settings. [50] Resistance among new cases, 
not being MDR, was also more common among prisoners than in the 
community. Strains belonging to the Beijing family occurred more often 
among isolates from prisoners than in the Arkhangelsk community, and 
there was a higher proportion (79,8%) than in the community (59,7%) of 
clustered isolates. [50, 66] The latter indicates a higher degree of 
transmission of the disease in the prison. In the isolates from prisoners 
clustered strains occurred more commonly among strains from the Beijing 





Through our studies we now have a better understanding of how 
complicated the matter of tuberculosis really is. According to the WHO the 
global prevalence in 2009 was at 14 million prevalent cases of active 
disease, and 1,3 million deaths due to TB (excluding deaths of the HIV 
positive). The Millennium Development Goal presented by the UN in 2000 
involved halving the prevalence within 2015, a goal that is by the looks of it 
out of reach as of today. The reasons why the situation is so severe and why 
it is so difficult to reverse the occurrence of the disease are many and 
diverse.  
 
The bacterium has a unique innate resistance to drug treatment and the 
human immune systems, with its structural characteristics, slow replication 
and being an intracellular organism. It has existed for thousands of years, 
and when effective drug treatment with antibiotics was discovered (and used 
in mono-therapy without adequate monitoring) it was the start of creating an 
epidemic of multi drug resistant disease. Later HIV has become a huge 
contributing factor to developing and dying from TB.  
There is also evidence that certain strains (as the Beijing strain) may be 
more virulent than other, and have a higher tendency of mutating, and these 
strains have accumulated in particular areas.  
 
It is both complicated regarding to logistics and expensive to diagnose TB 
in a proper way, and the huge amount of individuals with latent infection 
represent a practically endless amount of potential reservoirs of infection.  
 
Tuberculosis thrives on the weak, ill and poor in society, and this has 
become clear as the sub-Saharan countries have the highest prevalence of 
the disease. This is also where you find the highest accumulation of HIV. 
The Russian federation and other countries that departed from the Soviet 
Union in the early 1990s are other examples of high prevalence areas. These 
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are regions that struggle with a still increasing problem of multi drug 
resistance.  
 
Conditions during the soviet regime worsened a problem that was already 
considerable. Refusing to introduce modern treatment and harsh conditions 
in the many prisons are reasons that contributed to the high prevalence. As 
the soviet state resolved, economy in the new states collapsed, leaving 
people without housing, jobs and a proper health care systems. Again the 
prisons worsened the situation.  
 
The WHO has fought for decades to improve treatment of the disease, and 
keep introducing updated guidelines to help countries battle it. DOTS was 
launched in the 90s, and have by today helped treat more than 41 million 
patients. Later, as it has become obvious that resistance is on the rise, the 
DOTS plus guidelines were introduced. The WHO also has an invaluable 
role in monitoring epidemiologic factors.  
 
Between 1997-2000 there was an increase in global incidence rates by 0,4% 
per year. In the African region the incidence is as high as 345/100 000 
(2009), and this is also where you find 80% of the worlds HIV positive 
cases. In 2008 there were registered 440 000 cases of MDR-TB, and yet 
many are undiagnosed. Also there were 963 cases of XDR-TB, which is 
virtually impossible to treat in certain countries due to high expenses. New 
cases of MDR-TB in Russia were 15,8% in 2010, while some areas present 
as high numbers as close to 30%.  
 
Russia is an example of a country where they have gone to great measures 
to turn the negative trend. Well-organized systems for surveillance and 
reporting of MDR- and XDR-TB have been established in parts of Russia, 
following WHO guidelines.  
In the Arkhangelsk oblast TB-activities have been according to WHO 
recommendations for more than 10 years. Drug susceptibility testing has 
been performed in the central laboratory since 2004. The efforts displayed 
have caused a decrease in incidence over the last decade, however there are 
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8 Tables and Figures 
 
Table 1: Treatment schedules recommended by case or treatment category 
 
The medication is indicated by capital letters; numbers preceding the letters 
indicate the duration of treatment in months; numbers in subscript indicate 
the number of times per week the medications are given; when the letters 
are without subscript, the medications are given daily. E = Ethambutol, H = 













Tuberculosis case Recommended treatment schedule 
 Initial phase  Continuation phase  
1 - New case of smear-
positive PTB 
- Severe forms of smear-
negative PTB  
- Severe extra-pulmonary 
tuberculosis 
2 EHRZ (SHRZ) 
2 EHRZ (SHRZ) 
2 EHRZ (SHRZ) 
6 HE or 6 TH 
4 HR 
4 H3R3 
2 - Smear-positive 
pulmonary tuberculosis: 
   relapse 
   failure 
   return after interruption  
2 SHRZE/1 HRZE  





3 - Smear-negative PTB  












Combinations of second-line drugs reserved 
for used by the reference centres  
 
From: Maher D et al. Treatment of tuberculosis: guidelines for national programmes, 2nd ed.  
Geneva, World Health Organization, 1997 (document WHO/TB/97.220).  
 
The medications are indicated by capital letters; numbers preceding the letters indicate the 
duration of treatment in months; numbers in subscript indicate the number of times per week the 
medications are given; when the letters are without subscripts, the medications are given daily; 
e.g. 2EHRZ/4H3R3: daily administration of ethambutol, isoniazid, rifampicin and pyrazinamide 




Patient management  
 
Management of a patient involves a number of actions on which the success of the treatment 
depends. 
 
   Performing an assessment before starting treatment 
Before starting to treat a patient, a clinical assessment is necessary for the correct treatment 
regimen to be chosen. This involves the following steps: 
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Side-effects by symptom 
 
Side-effect  Drug responsible  Management  
Minor:  
- Pain in the joints  
- Burning sensations in the 
feet 









Pyridoxine 100 mg/day 
 
Take with food  
Major: 








- Visual impairment  
- Purpura, shock, acute 
kidney failure  
 
-  Thioacetazone or 
streptomycin 









Stop and do not give again 
(replace by ethambutol) 
Stop, then reintroduce with 
desensitization 
Stop and do not give again 
(replace by ethambutol) 
Stop until the jaundice 
disappears 
Stop and do not give again 
Stop and do not give again 
 
From: Maher D et al. Treatment of tuberculosis: guidelines for national programmes, 2nd ed.  
Geneva, World Health Organization, 1997 (document WHO/TB/97.220).  
 
It is easy to identify a side-effect when it is specific: thus purpura (rifampicin), vestibular 
problems (streptomycin), or the appearance of a scotoma in the field of vision (ethambutol) can 
immediately incriminate the drug in question, so it can be stopped immediately and a 
replacement drug selected. 
 
The problem is more complicated when a major side-effect occurs for which a number of drugs 
could be responsible, such as a skin reaction or jaundice (Appendix 6). 
 
Practical point 
Patients experiencing severe side-effects of medications should be referred to a physician 
experienced in the management of tuberculosis 
 
  Deciding on other treatment measures 
Apart from chemotherapy, which is necessary for treating all cases of tuberculosis, adjunctive 
therapy is indicated for certain sites. 
 
 Treatment with corticosteroids 
The addition of corticosteroids at a dose of 0.5 mg/kg per day for 3 to 6 weeks has been 




Table 3 Anti-tuberculosis drug and genes involved in resistance to the drug. 
 




From S.K. Sharma, A. Mohan. “Multidrug-Resistant Tuberculosis: A 
Menace That Threatens To Destabilize Tuberculosis Control”.  Chest. 2006 
Jul;130(1):261-72 
  
Isoniazid Enoyl acyl carrier protein (acp) reductase (inhA) 
 Catalase-peroxidase (katG) 
 Alkyl hydroperoxide reductase (ahpC) 
 Oxidative stress regulator (oxyR) 
 Β-Ketocyl acyl carrier protein synthase (kasA) 
Rifampicin RNA polymerase subunit B (rpoB) 
Pyrazinamide Pyrazinamidase (pncA) 
Streptomycin Ribosomal protein subunit 12 (rpsL) 
 16s ribosomal RNA (rrs) 
 Aminoglycoside phosphotransferase gene (strA) 
Capreomycin Haemolysin (tlyA) 
Ethambutol Arabinosyl transferase (emb A, emb  B and emb C) 
Fluoroquinolones DNA gyrase (gyr A and gyr B) 
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Figure 1. Estimated TB incidence rates, by country, 2009. 





Figure 2. Estimated HIV prevalence in new TB cases, 2009. 
Source: Global Tuberculosis Control 2010. WHO 2010. 
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